8-K Announcements
6Material company update
Apr 17, 2026·SEC
Material company update
Apr 10, 2026·SEC
Material company update
Mar 16, 2026·SEC
Lyra Therapeutics, Inc.(LYRA)Earnings, Financials & Key Ratios
LYRA•NASDAQ
$0.44
Price updated Jun 20, 2026
AboutLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$398K-74.1%
- EBITDA-$31M+68.1%
- Net Income-$29M+69.0%
- EPS (Diluted)-18.62-1202.1%
- Gross Margin100%
- EBITDA Margin-7679.15%-22.9%
- Operating Margin-7794.47%-24.1%
- Net Margin-7266.08%-19.3%
- ROE-6594.98%-3465.0%
LYRA Price & Volume
Lyra Therapeutics, Inc. (LYRA) stock price & volume — 10-year historical chart
Loading chart...
Severe Capital Erosion Threatens Lyra Therapeutics Solvency
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent insolvency and dilution
Key Thesis Takeaways
- Lyra Therapeutics faces a critical liquidity crisis as its revenue base has collapsed by 96.7% year-over-year to a negligible $7.0K, rendering the company unable to support its $4.4M quarterly R&D expenditure.
- The firm's transition to negative shareholder equity of -$10.7 million, coupled with a mounting debt burden of $30.3 million, suggests an imminent risk of insolvency.
- Investors should monitor the company's ability to secure dilutive financing, as the current cash runway of $15.9 million appears insufficient to sustain operations against persistent quarterly operating losses of $7.5 million.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $15.9 million against quarterly operating losses of $7.5 million, suggests a high probability of significant shareholder dilution or insolvency.
LYRA Growth Metrics
Lyra Therapeutics, Inc. (LYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-33.66%
TTM-74.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM69.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1202.1%
Return on Capital
10 Years-74.12%
5 Years-82.09%
3 Years-82.58%
Last Year-77.26%
Peers Comparison
Key metrics vs top competitors for Lyra Therapeutics, Inc. (LYRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.44 | $781.13K | -0.31 | -74.05% | -7266.08% | -6594.98% | — | |
| $15.67 | $1.15B | -12.64 | 13.65% | -185.71% | -28.77% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $1.85 | $5.13M | -0.30 | -18.3% | -1711.56% | -592.55% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $8.14 | $78.41M | 12.72 | — | -4088.84% | -127.3% | — |
Compare LYRA vs Peers
Lyra Therapeutics, Inc. (LYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LYRA SEC Filings & Documents
Lyra Therapeutics, Inc. (LYRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LYRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LYRA Frequently Asked Questions
Lyra Therapeutics, Inc. (LYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Lyra Therapeutics, Inc.'s revenue?
Lyra Therapeutics, Inc. (LYRA) reported $0.4M in revenue for fiscal year 2025. This represents a 68% decrease from $1.2M in 2018.
How fast is Lyra Therapeutics, Inc. growing?
Lyra Therapeutics, Inc. (LYRA) saw revenue decline by 74.1% over the past year.
Is LYRA profitable?
Lyra Therapeutics, Inc. (LYRA) reported a net loss of $28.9M for fiscal year 2025.
Dividend & Returns
What is LYRA's return on equity?
Lyra Therapeutics, Inc. (LYRA) has a return on equity (ROE) of -6595.0%. Negative ROE indicates the company is unprofitable.
What is Lyra Therapeutics, Inc.'s free cash flow?
Lyra Therapeutics, Inc. (LYRA) had negative free cash flow of $29.0M in fiscal year 2025, likely due to heavy capital investments.